AngioDynamics, Inc.

AngioDynamics, Inc.

ANGONYSE / NASDAQHealthcareSmall cap

$10.81+$0.05 (+0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$497.1M
P/E
-14.6x
EV / EBITDA
256.3x
Revenue
$292.5M
Net margin
-11.6%
ROCE
-11.8%

-5.3% over the last year

AngioDynamics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.5%
3M
-31.7%
6M
-8.5%
1Y
-5.3%
5Y
-62.1%

52-week range

Day change +$0.05 (+0.5%) from $10.76 to $10.81 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ANGO, bought on each weekday since 2021.

News & filings

What AngioDynamics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 34.0 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.03.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium.

Read moreShow less

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Sector
Healthcare
Shares outstanding
41.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$497.1M
P/E
-14.6x
P/B
2.7x
EV / EBITDA
256.3x
EV / Sales
1.5x
P/S
1.7x
52-week high
$16.13
52-week low
$9.70

Profitability

Operating margin
-8.2%
Net margin
-11.6%
EBITDA margin
0.6%
ROE
-18.6%
ROCE
-11.8%
ROIC
-15.0%
ROA
-12.1%
Asset turnover
1.04

Growth

Revenue
$292.5M
Revenue growth, 1Y
-3.8%
Revenue CAGR, 3Y
-2.6%
Net profit growth, 1Y
-81.6%
Free cash flow
-$14.6M

Solvency

Current ratio
2.21
Debt / Equity
0.03
Debt / Assets
0.02
CFO / Net profit
0.30
Cash / Market cap
11.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$292.5M
Cost of revenue$134.8M
Gross profit$157.7M
Operating expenses$181.8M
Research and development$26.2M
Selling, general and administrative$145.2M
Operating income-$24.1M
Interest and other-$10.0M
Pretax income-$34.0M
Tax and other-$40.0k
Net income-$34.0M

Revenue and net profit

Revenue fell 3.8% in FY2025; net profit is the dashed line.

AngioDynamics, Inc. revenue and net profit by fiscal year
AngioDynamics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$316.2M-$26.5M
FY2023$338.8M-$52.4M
FY2024$303.9M-$184.3M
FY2025$292.5M-$34.0M

Cash flows

FY2025: -$10.1M from operations, -$14.6M free after investment (dashed).

AngioDynamics, Inc. operating and free cash flow by fiscal year
AngioDynamics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$7.2M-$11.5M
FY2023$78.0k-$4.3M
FY2024-$28.2M-$33.9M
FY2025-$10.1M-$14.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$292.5M-3.8%1Y
EBITDA
$1.7M
Net profit
-$34.0M
Cash from operations
-$10.1M
Free cash flow
-$14.6M
Revenue CAGR, 3Y
-2.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$292.5M$1.7M-$34.0M-$14.6M-18.6%-3.8%-81.6%

Monthly returns

Month-by-month returns of ANGO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$280.1M
Liabilities$97.2M
Equity$183.0M
Paid-in capital$621.2M
Retained earnings-$429.2M
Treasury stock$7.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ANGO highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
AngioDynamics, Inc.ANGOthis company$497.1M-14.6x2.7x-18.6%256.3x
4D Molecular Therapeutics, Inc.FDMT$523.3M-3.7x1.0x-27.7%-3.2x
Aquestive Therapeutics, Inc.AQST$519.4M-6.2x-15.4x248.9%-6.7x
Pacific Biosciences of California, Inc.PACB$506.3M-0.9x94.6x-10214.5%-7.5x
Arvinas, Inc.ARVN$499.4M-6.2x1.2x-18.6%-3.2x
Standard BioTools Inc.LAB$495.8M-6.6x1.2x-17.7%-4.7x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
The Oncology Institute, Inc.TOI$473.9M-7.8x-30.1x385.5%-12.8x
Peer median—-5.0x1.2x-23.2%-4.2x

Year-to-date ROI

ANGO since 1 January, against earlier years.

Historical volatility

ANGO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

AngioDynamics, Inc. operating margin by fiscal year
AngioDynamics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-5.8%
FY2023-5.5%
FY2024-11.1%
FY2025-8.2%
LineFY2025
Cost of revenueCost Of Revenue$134.8M
Gross profitGross Profit$157.7M
Operating expensesOperating Expense$181.8M
Research and developmentResearch And Development$26.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$10.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$10.3M
Amortization$10.3M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$10.3M
Total expensesTotal Expenses$316.6M
Pretax incomePretax Income-$34.0M

Learn while you research

Academy chapters picked for AngioDynamics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →